Science that is transforming lives and enabling the future
Biopharma manufacturing is an essential part of the healthcare industry, producing lifesaving treatments for patients around the world. Traditional manufacturing methods can have a significant environmental impact driven by stainless steel equipment requiring extensive cleaning and sterilization processes that consume substantial amounts of water and energy in addition to cleaning agents.
For decades, the semiconductor device manufacturing mantra was “How do we make them smaller, cheaper, and faster?” The pursuit of Moore’s Law – the doubling of transistors on a chip every two years – was achieved through planar scaling. But that approach could only go on for so long. The mantra now is “How do we improve power, performance, area, and cost (PPAC)?” At the 14 nm node, it was clear that the best way to push the limits of semiconductor device PPAC was to take it into the third dimension.
Entegris is delighted to announce our collaboration with Agilitech, a pioneering partner to the biotech industry. Agilitech provides highly flexible, scalable, and future-proof single-use technologies for every step of the bioprocess. These include chromatography systems, mixers, and custom-tailored bioprocess controllers that scale from the laboratory to commercial production environments. This makes them a natural fit for the unique needs of life sciences customers.
Things are not always as they appear. Take semiconductor manufacturing. On the surface, it may seem that the secret to making semiconductor devices more advanced lies in the design. But just as an architect’s design for a building may not be structurally feasible without the right materials, a semiconductor device design may not be functional if the materials and their interactions are not considered and optimized.
By: Mike Lamach, Reach-In Sales Leader, FARRAR™ | Trane Technologies The explosion of needs for -80°C through -60°C assets over the past decade has been nothing short of remarkable. Clinical research investments keep expanding while commercial-scale needs continue to transform the landscape.
HOF Sonderanlagenbau GmbH has been a leader in freezer technology since 1988 under founders Hans-George Hof and Herrmann Schäfer in Lohra, Germany. Through technical knowledge and entrepreneurship, HOF has grown into a global freezer and service operation, specializing in freeze-drying systems for the pharmaceutical and biotechnology industries, serving 28 countries, with 40 customer sites and more than 100 freeze/thaw units serving the biotech and pharmaceutical market.
Whether you’re new to cold chain or a seasoned freeze/thaw pro, it can be difficult to find value-driven solutions for configuring freeze/thaw (F/T) biologic treatments and therapies. Complex cold chain demands are not one-size-fits-all and your team’s time is precious, which is why we created our Cold Chain Guidance Tool. This innovative tool guides you through common decision-making scenarios, analyzes your inputs, and provides you with an assessment of the biggest drivers to achieve optimal results from your process.
Here’s a challenge, say the number 9 out loud, nine times. 9, 9, 9, 9, 9, 9, 9, 9, 9.
To wrap up the Year of the Tiger (2022), there are still lessons to be learned from the animal kingdom. A tiger out in the open roaming the savannah is at risk of injuries from predators, including human hunters. Wafers left out in the open in a fab are susceptible to damage that can cause dramatic yield drops. The larger the wafer diameter, the greater the risk.
As the chief technologist for the Life Sciences Division at Trane Technologies, Scott Farrar knows a thing or two about ultra-low temperature control for the life sciences industry, perhaps drawing inspiration from his days at Penn State University enjoying peach ice cream. Scott’s biggest inspiration, however, was his entrepreneurial dad who started a solar equipment company, teaching Scott from a young age the importance of sciences, technology, engineering, and mathematics (STEM) education and solving problems. Scott carried those tools with him, and upon completing his formal education, went to work for a pharmaceutical manufacturing company in research and development, specializing in low-temp freezers and incubators as well as heat-momentum and mass-transfer-type processes for the pharmaceutical industry. His exposure to dilemmas and investigative approach is what drove him to create better customer experiences.
Like the human body, cell and gene therapy is complex. Specialized cells can be lost through age, injury or disease, and such loss cannot always be replenished by healthy cells, rendering the patient extremely sick or even fatally ill. In many cases, the patient has minimal time to live, with very few cells for transplantation. Thanks to advances in both cell and gene therapies, patients have options as these interventions continue to advance. Cellular therapy includes immunotherapies, vaccinations, and cancer vaccines. While gene therapy aims to modify or alter the biological properties of living cells for therapeutic use. As these interventions are distinct, their manufacturing processes often intersect, leaving opportunities for therapeutic enablement.
What do plasma chamber components have to do with deer or wild boar? These animals are potential sources of food for the tiger. The components are potential sources of contamination in the fab. Success in both cases relies on attention to detail and a flexible strategy. Whether you are chasing prey or particle contamination, a multi-pronged approach is best.